Abstract
Increased calcium and phosphate bone turnover in rapidly growing patients requires an augumentation in the intestinal calcium absorption which depends on 1,25/OH/2D. Catch up growth in the GH treated patients is therefore supposed to be a status which requires an increase of 1,25/OH/2D generation. To test this supposition we estimated serum 1,25/OH/2D in 22 pituitary dwarfs before and during growth spurt. The blood samples were collected before GH treatment, 11 days and 7 to 8 weeks after the replacement therapy was instituted. The significant raise in 1,25/OH/2D serum level during therapy was observed /20.8±8.0, 31.7±15.3, 34.1±17.0 pg/ml respectively/. This was more pronounced in children with less advanced skeletal maturation, lower stature and with better growth response to the replacement therapy. The 1,25/OH/2D serum concentration was not related to the prolactin level and to the deficiency of other pituitary hormones neither before nor after GH treatment.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Romer, T., Lorenc, R., Lukaszkiewicz, J. et al. Growth response for growth hormone/GH/replacement therapy. Pediatr Res 18, 1216 (1984). https://doi.org/10.1203/00006450-198411000-00092
Issue Date:
DOI: https://doi.org/10.1203/00006450-198411000-00092